{"abstract": "Sales of Sovaldi reached $3.5 billion in the second quarter, testifying to the effectiveness of the drug, which can essentially cure over 80 percent of patients with few side effects.", "web_url": "https://www.nytimes.com/2014/07/24/business/sales-of-hepatitis-c-drug-sovaldi-soar.html", "snippet": "Sales of Sovaldi reached $3.5 billion in the second quarter, testifying to the effectiveness of the drug, which can essentially cure over 80 percent of patients with few side effects.", "lead_paragraph": "Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, a huge figure that puts it on track to become one of the world\u2019s best-selling medicines but could intensify concerns about society\u2019s ability to pay for it.", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-articleLarge.jpg", "height": 910, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 910}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-jumbo.jpg", "height": 1024, "width": 675, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-superJumbo.jpg", "height": 1898, "width": 1251, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Gilead\u2019s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster", "kicker": null, "content_kicker": null, "print_headline": "Strong Sales of Hepatitis C Drug Put It on Pace to Become a Blockbuster", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Gilead Sciences Inc", "rank": 1, "major": "N"}, {"name": "persons", "value": "Pollack, Andrew", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Hepatitis", "rank": 4, "major": "N"}, {"name": "subject", "value": "Sovaldi (Drug)", "rank": 5, "major": "N"}, {"name": "subject", "value": "Health Insurance and Managed Care", "rank": 6, "major": "N"}, {"name": "organizations", "value": "AbbVie Inc", "rank": 7, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 8, "major": "N"}], "pub_date": "2014-07-23T20:54:31+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/15384d26-ba47-50b6-8e4e-b8bc6ad35285", "word_count": 978, "uri": "nyt://article/15384d26-ba47-50b6-8e4e-b8bc6ad35285"}